Search
for
Sort by
Research 30 of 630
- Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors
- Present Chemotherapy Induced Alopecia and Research in Future
- Index
- Alopecia in patients treated with molecularly targeted anticancer therapies
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma
- Identifying the supportive care needs of men and women affected by chemotherapy-induced alopecia? A systematic review
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects
- A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma – the DUCT study protocol
- Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
- Management of Toxicities of Targeted Therapies
- Síndrome PRIDE: una práctica forma de identificar los efectos adversos cutáneos de los inhibidores del EGFR
- Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
- Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis
- Management of Cutaneous and Extracutaneous Side Effects of Smoothened Inhibitor Therapy for Advanced Basal Cell Carcinoma
- Dermatologic Adverse Events from Cancer Treatments
- The efficacy of scalp cooling in patients receiving chemotherapy for primary gynecologic cancers: a randomized controlled trial
- Radiotherapy-Induced Skin Fibrosis: Pathophysiology, Emerging Therapeutics, and the Role of Dermatology
- Topical Application of Aprepitant Inhibits Erlotinib-induced Facial Dermatitis/Hair Loss
- Target-Adverse Events and Fear of Cancer Progression, Anxiety, and Depression in Patients with Advanced Non-Small Cell Lung Cancer
- Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment
- Effect of a medicinal and edible decoction YH0618 on chemotherapy-induced dermatologic toxicity: a randomized controlled trial
- Safety profile of CAP7.1 obtained during Phase I Trial in adult patients with refractory malignancies
- Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
- The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial
- Scalp cooling versus standard cold-cap in preventing chemotherapy-induced alopecia in patients with localized breast cancer: ICELAND protocol, a randomized controlled trial and economic evaluation
- Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis